Research
Hormonal
Sibutramine, an appetite suppressant acting on the hypothalamus, is more effective than placebo for weight loss when combined with lifestyle changes, with 22-38% of patients achieving >5% weight loss in 3 months.
Sibutramine helps you lose weight by reducing appetite. About 22-38% of users lose more than 5% of their body weight in 3 months. It is not safe for people with heart problems or high cardiovascular risk. Side effects include increased blood pressure and dry mouth.
GoodSupportsHIGH confidence
Em estudos de meta-análise, esse fármaco se mostrou eficaz quando utilizado em combinação a modificações do estilo de vida em pessoas obesas, sendo, mais eficaz para a perda de peso que o placebo... A proporção de pacientes que superaram perdas de peso acima de 5%, foi de 22-38% dos pacientes em uso da farmacoterapia, em 3 meses.
Why this rating
Based on meta-analyses and clinical studies.
Source
TERAPIAS FARMACOLÓGICAS PARA TRATAR OBESIDADE: ANÁLISE DE EFEITO E EFICÁCIA
Túlio Martins Freitas et al. · Revista Foco · 2024
DOI 10.54751/revistafoco.v17n10-082
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide, administered via weekly subcutaneous injection, produces significant weight loss (mean 14.9% reduction) and improves insulin resistance, hypertension, and glycemia in adults with obesity (BMI ≥30 kg/m²).Strong
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant weight loss (up to -9.5 kg with 15 mg dose) in patients with type 2 diabetes over 40 weeks.Strong
- Orlistat, taken at 120 mg three times daily, reduces body weight by 8% over 12 months compared to 5% with placebo, and significantly reduces cardiovascular risk factors like hypertension and LDL cholesterol.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →